MCM3AP‑AS1 promotes cisplatin resistance in gastric cancer cells via the miR‑138/FOXC1 axis

Sun,Han; Wu,Ping; Zhang,Bao; Wu,Xia; Chen,Weixu

doi:10.3892/ol.2021.12472

MCM3AP‑AS1 promotes cisplatin resistance in gastric cancer cells via the miR‑138/FOXC1 axis

Authors:
- Han Sun
- Ping Wu
- Bao Zhang
- Xia Wu
- Weixu Chen
View Affiliations

Affiliations: Department of Digestive Internal Medicine, Xuzhou Central Hospital, Xuzhou, Jiangsu 221000, P.R. China
Published online on: January 18, 2021 https://doi.org/10.3892/ol.2021.12472
Article Number: 211
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The dysregulation of long non‑coding RNAs (lncRNAs) serves a pivotal role in the pathogenesis and development of multiple types of human cancer, including gastric cancer (GC). MCM3AP‑antisense 1 (MCM3AP‑AS1) has been reported to function as a tumor promoter in various types of cancer. However, the biological function of MCM3AP‑AS1 in the resistance of GC cells to cisplatin (CDDP) remains to be elucidated. The present study aimed to elucidate the mechanisms of MCM3AP‑AS1 in the resistance of GC cells to CDDP. The expression levels of MCM3AP‑AS1, miR‑138 and FOXC1 were measured via reverse transcription‑quantitative PCR. In addition, cell viability, migration and invasion were assessed via the Cell Counting Kit‑8, wound healing and transwell assays, respectively. The interaction between genes was confirmed via the dual‑luciferase reporter and pull‑down assays. Western blot analysis was performed to detect FOXC1 protein expression. In the present study, it was demonstrated that MCM3AP‑AS1 expression was upregulated in CDDP‑resistant GC cells and that MCM3AP‑AS1‑knockdown suppressed CDDP resistance in GC cells. Moreover, the examination of the molecular mechanism indicated that MCM3AP‑AS1 upregulated FOXC1 expression by sponging microRNA (miR)‑138. Additionally, it was identified that the overexpression of FOXC1 abolished MCM3AP‑AS1‑knockdown‑ or miR‑138 mimic‑mediated inhibitory effects on CDDP resistance in GC cells. In conclusion, the present findings suggested that MCM3AP‑AS1 enhanced CDDP resistance by sponging miR‑138 to upregulate FOXC1 expression, indicating that MCM3AP‑AS1 may be a novel promising biomarker for the diagnosis and treatment of patients with GC.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
3	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
4	Wadhwa R, Taketa T, Sudo K, Blum MA and Ajani JA: Modern oncological approaches to gastric adenocarcinoma. Gastroenterol Clin North Am. 42:359–369. 2013. View Article : Google Scholar : PubMed/NCBI
5	Ashraf N, Hoffe S and Kim R: Adjuvant treatment for gastric cancer: Chemotherapy versus radiation. Oncologist. 18:1013–1021. 2013. View Article : Google Scholar : PubMed/NCBI
6	Ghosh S: Cisplatin: The first metal based anticancer drug. Bioorg Chem. 88:1029252019. View Article : Google Scholar : PubMed/NCBI
7	Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar : PubMed/NCBI
8	Chen LL: Linking long noncoding RNA localization and function. Trends Biochem Sci. 41:761–772. 2016. View Article : Google Scholar : PubMed/NCBI
9	Prensner JR and Chinnaiyan AM: The emergence of lncRNAs in cancer biology. Cancer Discov. 1:391–407. 2011. View Article : Google Scholar : PubMed/NCBI
10	Wu M, Huang Y, Chen T, Wang W, Yang S, Ye Z and Xi X: lncRNA MEG3 inhibits the progression of prostate cancer by modulating miR-9-5p/QKI-5 axis. J Cell Mol Med. 23:29–38. 2019. View Article : Google Scholar : PubMed/NCBI
11	Gao W, Weng T, Wang L, Shi B, Meng W, Wang X, Wu Y, Jin L and Fei L: Long non-coding RNA NORAD promotes cell proliferation and glycolysis in non-small cell lung cancer by acting as a sponge for miR1365p. Mol Med Rep. 19:5397–5405. 2019.PubMed/NCBI
12	Xu N, Qiao L, Yin L and Li H: Long noncoding RNA ROR1-AS1 enhances lung adenocarcinoma metastasis and induces epithelial-mesenchymal transition by sponging miR-375. J BUON. 24:2273–2279. 2019.PubMed/NCBI
13	Zhang M, Jiang X, Jiang S, Guo Z, Zhou Q and He J: lncRNA FOXD2-AS1 regulates miR-25-3p/Sema4c axis to promote the invasion and migration of colorectal cancer cells. Cancer Manag Res. 11:10633–10639. 2019. View Article : Google Scholar : PubMed/NCBI
14	Xi Z, Si J and Nan J: lncRNA MALAT1 potentiates autophagy-associated cisplatin resistance by regulating the microRNA-30b/autophagy-related gene 5 axis in gastric cancer. Int J Oncol. 54:239–248. 2019.PubMed/NCBI
15	Guo Y, Yue P, Wang Y, Chen G and Li Y: PCAT-1 contributes to cisplatin resistance in gastric cancer through miR-128/ZEB1 axis. Biomed Pharmacother. 118:1092552019. View Article : Google Scholar : PubMed/NCBI
16	Liu L and Wang S: Long non-coding RNA OIP5-AS1 knockdown enhances CDDP sensitivity in osteosarcoma via miR-377-3p/FOSL2 axis. Onco Targets Ther. 13:3853–3866. 2020. View Article : Google Scholar : PubMed/NCBI
17	Yang M, Sun S, Guo Y, Qin J and Liu G: Long non-coding RNA MCM3AP-AS1 promotes growth and migration through modulating FOXK1 by sponging miR-138-5p in pancreatic cancer. Mol Med. 25:552019. View Article : Google Scholar : PubMed/NCBI
18	Zhang H, Luo C and Zhang G: lncRNA MCM3AP-AS1 regulates epidermal growth factor receptor and autophagy to promote hepatocellular carcinoma metastasis by interacting with miR-455. DNA Cell Biol. 38:857–864. 2019. View Article : Google Scholar : PubMed/NCBI
19	Chen Q, Xu H, Zhu J, Feng K and Hu C: lncRNA MCM3AP-AS1 promotes breast cancer progression via modulating miR-28-5p/CENPF axis. Biomed Pharmacother. 128:1102892020. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Kong X, Duan Y, Sang Y, Li Y, Zhang H, Liang Y, Liu Y, Zhang N and Yang Q: lncRNA-CDC6 promotes breast cancer progression and function as ceRNA to target CDC6 by sponging microRNA-215. J Cell Physiol. 234:9105–9117. 2019. View Article : Google Scholar : PubMed/NCBI
22	Li B, Mao R, Liu C, Zhang W, Tang Y and Guo Z: lncRNA FAL1 promotes cell proliferation and migration by acting as a CeRNA of miR-1236 in hepatocellular carcinoma cells. Life Sci. 197:122–129. 2018. View Article : Google Scholar : PubMed/NCBI
23	Xu Y, Shao QS, Yao HB, Jin Y, Ma YY and Jia LH: Overexpression of FOXC1 correlates with poor prognosis in gastric cancer patients. Histopathology. 64:963–970. 2014. View Article : Google Scholar : PubMed/NCBI
24	Hu Y, Zhu QN, Deng JL, Li ZX, Wang G and Zhu YS: Emerging role of long non-coding RNAs in cisplatin resistance. Onco Targets Ther. 11:3185–3194. 2018. View Article : Google Scholar : PubMed/NCBI
25	Ye Y, Yang S, Han Y, Sun J, Xv L, Wu L and Ming L: HOXD-AS1 confers cisplatin resistance in gastric cancer through epigenetically silencing PDCD4 via recruiting EZH2. Open Biol. 9:1900682019. View Article : Google Scholar : PubMed/NCBI
26	An J, Lv W and Zhang Y: lncRNA NEAT1 contributes to paclitaxel resistance of ovarian cancer cells by regulating ZEB1 expression via miR-194. Onco Targets Ther. 10:5377–5390. 2017. View Article : Google Scholar : PubMed/NCBI
27	Mendell JT: MicroRNAs: Critical regulators of development, cellular physiology and malignancy. Cell Cycle. 4:1179–1184. 2005. View Article : Google Scholar : PubMed/NCBI
28	He L and Hannon GJ: MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004. View Article : Google Scholar : PubMed/NCBI
29	Hu X, Zhang M, Miao J, Wang X and Huang C: miRNA-4317 suppresses human gastric cancer cell proliferation by targeting ZNF322. Cell Biol Int. 42:923–930. 2018. View Article : Google Scholar : PubMed/NCBI
30	He X and Zou K: miRNA-96-5p contributed to the proliferation of gastric cancer cells by targeting FOXO3. J Biochem. 167:101–108. 2020. View Article : Google Scholar : PubMed/NCBI
31	Yeh YM, Chuang CM, Chao KC and Wang LH: MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1α. Int J Cancer. 133:867–878. 2013. View Article : Google Scholar : PubMed/NCBI
32	Zhang J, Liu D, Feng Z, Mao J, Zhang C, Lu Y, Li J, Zhang Q, Li Q and Li L: MicroRNA-138 modulates metastasis and EMT in breast cancer cells by targeting vimentin. Biomed Pharmacother. 77:135–141. 2016. View Article : Google Scholar : PubMed/NCBI
33	Zhu D, Gu L, Li Z, Jin W, Lu Q and Ren T: miR-138-5p suppresses lung adenocarcinoma cell epithelial-mesenchymal transition, proliferation and metastasis by targeting ZEB2. Pathol Res Pract. 215:861–872. 2019. View Article : Google Scholar : PubMed/NCBI
34	Tang X, Jiang J, Zhu J, He N and Tan J: HOXA4-regulated miR-138 suppresses proliferation and gefitinib resistance in non-small cell lung cancer. Mol Genet Genomics. 294:85–93. 2019. View Article : Google Scholar : PubMed/NCBI
35	Li B, Zhao H, Song J, Wang F and Chen M: LINC00174 down-regulation decreases chemoresistance to temozolomide in human glioma cells by regulating miR-138-5p/SOX9 axis. Hum Cell. 33:159–174. 2020. View Article : Google Scholar : PubMed/NCBI
36	Chan JJ and Tay Y: Noncoding RNA:RNA regulatory networks in cancer. Int J Mol Sci. 19:13102018. View Article : Google Scholar
37	Chen M, Zhang R, Lu L, Du J, Chen C, Ding K, Wei X, Zhang G, Huang Y and Hou J: lncRNA PVT1 accelerates malignant phenotypes of bladder cancer cells by modulating miR-194-5p/BCLAF1 axis as a ceRNA. Aging (Albany NY). 12:22291–22312. 2020. View Article : Google Scholar : PubMed/NCBI
38	Zhang Y, Li W, Lin Z, Hu J, Wang J, Ren Y, Wei B, Fan Y and Yang Y: The long noncoding RNA Linc01833 enhances lung adenocarcinoma progression via miR-519e-3p/S100A4 axis. Cancer Manag Res. 12:11157–11167. 2020. View Article : Google Scholar : PubMed/NCBI
39	Yun SH, Han SH and Park JI: COUP-TFII knock-down promotes proliferation and invasion in colorectal cancer cells via activation of Akt pathway and up-regulation of FOXC1. Anticancer Res. 40:177–190. 2020. View Article : Google Scholar : PubMed/NCBI
40	Gong R, Lin W, Gao A, Liu Y, Li J, Sun M, Chen X, Han S, Men C, Sun Y and Liu J: Forkhead box C1 promotes metastasis and invasion of non-small cell lung cancer by binding directly to the lysyl oxidase promoter. Cancer Sci. 110:3663–3676. 2019. View Article : Google Scholar : PubMed/NCBI
41	Huang H, Xiong Y, Wu Z, He Y, Gao X, Zhou Z and Wang T: MIR-138-5P inhibits the progression of prostate cancer by targeting FOXC1. Mol Genet Genomic Med. 8:e11932020. View Article : Google Scholar : PubMed/NCBI